Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Phase 1

Completed

• Conditions: Actinic Keratosis
• Interventions: Drug: LEO 43204 gel 0.018%; Drug: LEO 43204 gel 0.1%; Drug: LEO 43204 gel 0.037%

• Registration Number: NCT02424305
• Lead Sponsor: LEO Pharma

Brief Summary

This is an open-label, uncontrolled, non-randomised multi-centre trial in which 3 parallel groups will be enrolled. The trial includes three active treatment groups. To be eligible for inclusion in this trial, subjects must have at least 15 clinically typical, visible, and discrete actinic keratosis (AKs) on the face, scalp or on the arm within a contiguous area of approximately 250 cm2 of sun-damaged skin.

There will be 3 treatment groups: (1) once daily application of LEO43204 gel 0.018% on the full face for three consecutive days, (2) once daily application of LEO43204 gel 0.1% on the arm on a treatment area of approximately 250 cm2 for three consecutive days and , (3) once daily application of LEO43204 gel 0.037 % on the scalp for three consecutive days.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-04-14
• Study First Submitted QC: 2015-04-22
• Study First Posted: 2015-04-23
• Study Start: 2015-05
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Status Verified: 2017-05
• Last Update Submitted: 2025-02-21
• Last Update Posted: 2025-02-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Subjects with 15 or more clinically typical, visible and discrete AKs on either:

   • Full face (corresponding to a treatment area of at least 250 cm2). If subjects have a beard they must shave no later than the day before the first drug application.
   • A contiguous area of approximately 250 cm2 on the arm between wrist and shoulder.
   • Balding scalp (corresponding to a treatment area of approximately 250 cm2). Subjects with sparse hair on the scalp can be enrolled as long as LSR and AK assessments are not compromised.

2. Subject at least 18 years of age.

3. Female subjects of childbearing potential* must be confirmed not pregnant by a negative urine pregnancy test prior to trial treatment.

4. Female subjects of childbearing potential must be willing to use effective contraception at trial entry and until completion.

Exclusion Criteria

1. Location of the treatment area (full face, full balding scalp, chest, trunk or extremities)

   • within 5 cm of an incompletely healed wound.
   • within 5 cm of a suspected basal cell carcinoma (BCC) or SCC.

2. Previously assigned treatment in this clinical trial or previously participated in a clinical trial in the LEO 43204 programme.

3. Lesions in the treatment area that have: atypical clinical appearance (e.g. cutaneous horns)and/or, recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
face: LEO 43204 gel 0.018%	LEO 43204 gel 0.018%	3 days treatment (once daily) on face: LEO 43204 gel 0.018%
arm: LEO 43204 gel 0.1%	LEO 43204 gel 0.1%	3 days treatment (once daily) on arm: LEO 43204 gel 0.1%
scalp: LEO 43204 gel 0.037%	LEO 43204 gel 0.037%	3 days treatment (once daily) on scalp: LEO 43204 gel 0.037%

Primary Outcome Measures

Name	Time	Method
Area under the plasma concentration versus time curve (AUC) of LEO 43204.	Once daily for 3 days
Peak Plasma Concentration (Cmax) of LEO 43204.	Once daily for 3 days

Trial Locations

Locations (1)

Pflugerville Dermatology Clinical Research; 🇺🇸 Pflugerville, Texas, United States